Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
EMERYVILLE, Calif., Feb. 03, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
| LEERINK Partners 5th Annual Global Healthcare Conference -- Zogenix Presentation Details | |
| Date: | Wednesday, February 10, 2016 |
| Time: | 10:40 am Eastern Time / 7:40 am Pacific Time |
| Location: | New York, NY - The Waldorf Astoria Hotel, Metropolitan Suite |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
